Sun Pharmaceutical Industries Limited
Acquisition Details
Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or affiliates referred to as "Sun Pharma" or "Company") has entered into an agreement to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited.
Target Company Information
Name: Innovcare Lifesciences Private Limited
Business: Marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products.
Incorporation Date: 21 July 2014
Financial Performance of Target
Revenue from Operations:
- FY 2025-26: ₹94.06 Crores
- FY 2024-25: ₹86.09 Crores
- FY 2023-24: ₹80.93 Crores
Transaction Specifics
Consideration Type: Cash Consideration
Cost of Acquisition: Cash consideration aggregating approximately ₹271.2 Crores.
Completion Timeline: The acquisition is to be completed on or before 31 July 2026.
Transaction Rationale and Nature
The acquisition is described as a strategic investment to strengthen the product portfolio of Sun Pharma. The transaction is not a related party transaction, and the promoter/promoter group does not have any interest in Innovcare Lifesciences.
Regulatory Approvals
No governmental or regulatory approvals are required for this acquisition.
Compliance and Signatory
The disclosure is made as per Regulation 30 and Part A of Schedule III. It is signed by Anoop Deshpande, Company Secretary and Compliance Officer (ICSI Membership No.: A23983), on 20 June 2026.
#SunPharmaceutical #Acquisition #SEBIRegulation30 #M&A #Pharmaceuticals